Updated 18:03 GMT, 5 Nov 2026 SPX 7,427.81 -3.39% NDX 26,945.57 -5.25% VIX 23.84 +43.53% GOLD 4,132.30 +1.46% CL 90.22 +2.38% BTC 75,632.84 -5.94%
NAS100 26,946 −5.25% S&P 7,428 −3.39% GOLD $4,132 +1.46% BTC $75,633 −5.94% VIX 23.84 +43.53% latest tape · as of 18:03 UTC
The Screen · Basic Materials · Steel

Metallus Inc.

MTUS · the NYSE · USD · Market cap $837M · 1,890 employees

Metallus Inc.

PASS · Titan Ethical · score 70.0
17.87 USD

Price as of 4 Nov 2026Daily close, not a live quote

Screened 2026-11-04 · the tape above runs as of 18:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price17.87 USD at the 4 Nov 2026 close
  • Our value readFair vs our fair value, as of 4 Nov 2026
  • Our regime readMarkdown, as of 4 Nov 2026
  • Ethical screenPasses, score 70.0 out of 100
  • OptionsOpen interest leans heavily to calls (put/call 0.27)
  • Last reviewed4 Nov 2026 (1 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $17.88 to $20.57, base estimate $17.88 (screen dated 2026-11-04).

Current read
Markdown ?
Fair · screened 2026-11-04
  • Trend Markdown
  • Insiders insiders sold, $102,146, latest filing 2026-11-02
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.27, read 2026-11-05
  • Ethical passes the values gate
Price17.87 USD
Fair value17.88
Ethical score70.0/100
Value readFairas of 4 Nov 2026
Our investment reviews on this name
2026-10-11Read Accumulation19.97-10.5% to today Markdown gives way to Accumulation after a 6% rise in 5 weeks
2026-09-06Read Markdown18.88-5.3% to today ✓Markup gives way to Markdown after an 8% slide in 9 weeks
2026-07-02Read Markup20.48-12.7% to today First review on file: Markup

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markdown label.

Metallus Inc. holds its Markdown at $17.87. Consolidating, no directional conviction, held for 155 days.

As held on the ledger · 2026-11-04
PhaseMarkdown · caution
Quantitative stateConsolidating, no directional conviction, held for 155 days
Price at the screen$17.87
Valuation105.84 trailing · 14.44 forward price to earnings
Values screenPASS · score 70.0
Beta1.37
The Workings

Five Screens, Shown in Full

Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 1.31% Below 33% Interest-bearing debt is just 1.3% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 24.79% Below 49% Money owed to the company is 24.8% of assets, under the 49% limit. Pass
Revenue purity 0.58% Below 5% Only 0.6% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Clears, in Plain English

Metallus clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.

Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when MTUS's ethical verdict changes

Today MTUS passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Fair vs our fair value, as of 4 Nov 2026: it trades at roughly a 0% discount to our $17.88 fair value, 12.00% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

17.88Conservative17.88Base case20.57Growth case 17.87Price

Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 0.1% discount to the base estimate.

The Street's Range
24.00Street low 24.00Street average 24.24Street high 17.87Price

Third-party analyst targets. The average target sits +34% from the screen price.

Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.

Price History & Projections

Where our models see it going: fair-value estimate $17.88, with a range of $17.88 to $20.57, dated to the 2026-11-04 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Why it is worth knowing

A quality business. It trades close to our $17.88 fair value, so the easy discount is gone; you would be paying up for the quality.

The fundamentals · plain-English read
Forward P/E14.4xpriced for continued growth
Trailing P/E105.8xexpensive: the price assumes strong growth ahead
EPS, trailing0.19
EPS, forward1.39
Revenue growth+12.0%steady growth
Profit margin0.7%barely profitable
Return on equity1.2%a modest return on shareholder capital
FCF yield-7.45%
Debt to equity2.12heavy leverage: higher risk if revenue softens
Current ratio1.75healthy short-term liquidity
Beta1.37moves a little more than the market
Short interest, float0.07%
52-week range14.19 - 22.58
Market cap$837M
Employees1,890

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

MTUS trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-02 Accumulation $21.12 +0.0% Entry 17

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $22. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-01 Accumulation $21.12 +0.0% Entry 16

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $22. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-31 Accumulation $21.12 -1.4% Entry 15

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $22. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-30 Accumulation $21.42 +1.4% Entry 14

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $22. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-29 Accumulation $21.13 +5.1% Entry 13

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $22. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-28 Accumulation $20.11 +0.0% Entry 12

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $22. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-27 Accumulation $20.11 +0.0% Entry 11

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $22. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-26 Accumulation $20.11 +0.0% Entry 10

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $22. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-25 Accumulation $20.11 -1.5% Entry 9

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 8% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $22. Insiders have been net sellers over the past quarter.

2026-10-18 Accumulation $20.42 +2.3% Entry 8

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Over the past year the shares are up 36%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (2 analysts) rates it none, with a mean price target of $22. Insiders have been net sellers over the past quarter.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on MTUS

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in MTUS's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · MTUS
DateInsiderTitleTypeSharesValue
2026-11-02 Syrvalin Kristine C EVP GC S - Sale+OE 4,643 $102,146
2026-11-02 Williams Michael S CEO S - Sale 985 $21,673
2026-11-02 Raketich Kevin A EVP, Strategy, Corp. Dev. S - Sale 1,080 $23,760
2026-10-02 Williams Michael S CEO S - Sale 12,570 $251,483

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $18.31 +8.1% · $1,081 +8.1%
2 months $17.74 +11.6% · $1,116 +11.6%
3 months $15.22 +30.0% · $1,300 +30.0%
6 months $18.40 +7.6% · $1,076 +7.6%
1 year $14.58 +35.7% · $1,357 +35.7%
2 years $21.92 -9.7% · $903 -9.7%
3 years $18.85 +5.0% · $1,050 +5.0%
5 years $15.99 +23.8% · $1,238 +23.8%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever MTUS does next, these words stay.

Metallus Inc. · MTUS · Markdown · $17.87
Recorded 2026-11-04 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.